Pravafenix | European Medicines Agency (EMA)

[ad_1]

Overview

Pravafenix is used in adults at high risk of heart disease whose low-density-lipoprotein (LDL) cholesterol is already being controlled with pravastatin alone or another medicine from the statin family, but who still need to improve their high-density-lipoprotein (HDL) cholesterol levels and reduce their levels of triglycerides (another type of fat) in the blood. Pravafenix is used in addition to other measures such as diet, exercise and weight reduction.

Pravafenix contains the active substances pravastatin and fenofibrate.

Pravafenix can only be obtained with a prescription. It is available as capsules to be taken by mouth once a day with food, during the evening meal. Before starting treatment with Pravafenix, the doctor should first investigate all possible causes of the patient’s abnormal cholesterol and triglyceride blood levels and recommend a suitable diet.

The patient’s blood should be monitored regularly to see how the medicine is working. The doctor should stop treatment if an adequate response does not occur within three months.

The active substances in Pravafenix, pravastatin and fenofibrate, work in different ways and their actions have a complementary effect.

Pravastatin belongs to a group of medicines called statins. It reduces total blood cholesterol by blocking the action of the HMG-CoA reductase, an enzyme (protein) in the liver involved in the production of cholesterol. As the liver needs cholesterol to produce bile, the reduced blood cholesterol level causes the liver cells to produce receptors that draw LDL cholesterol from the blood, reducing its level even further.

Fenofibrate attaches to the peroxisome proliferator‑activated receptor alpha (PPAR alpha), which is involved in breaking down fat from the diet, especially triglycerides. When the receptors are activated, the breakdown of fats is accelerated, and this helps clear the blood of cholesterol and triglycerides.

Because pravastatin and fenofibrate have been used in clinical practice for a long time, the company presented information from the scientific literature. Additionally, a main study showed that Pravafenix is more effective than pravastatin alone in reducing blood levels of non-HDL cholesterol.

The main study involved 248 patients at high risk of heart disease who had abnormal levels of cholesterol and triglycerides in the blood. Patients were either treated with Pravafenix or pravastatin alone. After 12 weeks of treatment, non-HDL cholesterol was reduced by an average of around 14% in patients taking Pravafenix, compared with an average of around 6% in patients taking pravastatin alone.

An additional study confirmed the effectiveness of Pravafenix compared with other statin medicines given alone in patients treated by different doctors such as family doctors, cardiologists or endocrinologists.

For the complete list of side effects and restrictions with Pravafenix, see the package leaflet.

The most common side effects with Pravafenix (which may affect up to 1 in 10 people) include abdominal distension (bloating), abdominal (belly) pain, constipation, diarrhoea, dry mouth, dyspepsia (heartburn), eructation (belching), flatulence (gas), nausea (feeling sick), abdominal discomfort, vomiting and raised blood levels of liver enzymes.

Pravafenix must not be used in patients aged less than 18 years or in patients with severe liver problems, moderate to severe kidney problems, photo allergy or phototoxic reactions (allergic reaction or skin damage due to light exposure) during treatment with fibrates or ketoprofen medicines. It must also not be used in patients with gall bladder disease, chronic or acute pancreatitis (inflammation of the pancreas) or a history of myopathy (muscle disorders) or rhabdomyolysis (breakdown of muscle fibres) following treatment with a statin or fibrate medicine. It must not be taken by women who are pregnant or breastfeeding.

Data from the scientific literature and from two studies show that Pravafenix, which combines a statin and fenofibrate, is more effective than a statin alone to reduce LDL cholesterol in patients who have high levels of triglycerides and low levels of HDL cholesterol. Regarding safety, side effects with Pravafenix were considered acceptable for the patients in which it is used.

The European Medicines Agency therefore decided that Pravafenix’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pravafenix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pravafenix are continuously monitored. Suspected side effects reported with Pravafenix are carefully evaluated and any necessary action taken to protect patients.

Pravafenix received a marketing authorisation valid throughout EU on 14 April 2011.

English (EN)
(117.1 KB – PDF)

First published: 17/05/2011Last updated: 17/01/2025

View

Product information

English (EN)
(490.96 KB – PDF)

First published: 17/05/2011Last updated: 17/01/2025

View

Latest procedure affecting product information:
II/0037

21/10/2024

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(25.15 KB – PDF)

First published: 17/05/2011Last updated: 29/08/2013

View

Product details

Name of medicine: Pravafenix
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH): Dyslipidemias
Anatomical therapeutic chemical (ATC) code: C10BA03

Pharmacotherapeutic group

Lipid modifying agents

Therapeutic indication

Pravafenix is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the treatment of mixed hyperlipidaemia in adult patients at high cardiovascular risk to reduce triglycerides and increase HDL C when LDL C levels are adequately controlled while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen.

[ad_2]

Source link

Subscribe now

To access premium content

Ubisoft To Develop Blockchain Games, Enjin’s $100 Million Fund

All About Play to Earn With Crypto Games (P2E)

Blockchain Gaming Industry & 5 Crypto Games to Watch

Ethereum Still Leads The Way in Blockchain Gaming

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead